AstraZeneca Pharma India Limited (BOM:506820)
India
· Delayed Price · Currency is INR 8,291.10
-126.10 (-1.50%)
At close: Aug 14, 2025
AstraZeneca Pharma India Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| Cash & Equivalents | - | 5,361 | 5,056 | 5,003 | 4,484 | 3,523 | Upgrade
|
| Cash & Short-Term Investments | 5,361 | 5,361 | 5,056 | 5,003 | 4,484 | 3,523 | Upgrade
|
| Cash Growth | 6.05% | 6.05% | 1.04% | 11.58% | 27.27% | 39.54% | Upgrade
|
| Accounts Receivable | - | 1,849 | 1,531 | 1,075 | 858.9 | 851.9 | Upgrade
|
| Other Receivables | - | 143.6 | 160.4 | 105.1 | 121.8 | 56.6 | Upgrade
|
| Receivables | - | 1,995 | 1,693 | 1,181 | 981.6 | 911.2 | Upgrade
|
| Inventory | - | 5,485 | 2,279 | 1,902 | 1,402 | 1,598 | Upgrade
|
| Prepaid Expenses | - | 142.1 | 109.6 | 117.7 | 108.2 | 83.9 | Upgrade
|
| Other Current Assets | - | 439.6 | 190 | 150.4 | 80.5 | 71.1 | Upgrade
|
| Total Current Assets | - | 13,424 | 9,327 | 8,355 | 7,057 | 6,188 | Upgrade
|
| Property, Plant & Equipment | - | 635.8 | 648.4 | 701.9 | 766.9 | 849.8 | Upgrade
|
| Other Intangible Assets | - | 6.6 | 21.1 | - | - | - | Upgrade
|
| Long-Term Deferred Tax Assets | - | 415.6 | 212.5 | 206.7 | 163 | 145.3 | Upgrade
|
| Other Long-Term Assets | - | 698.6 | 568.5 | 576.6 | 574.9 | 560.1 | Upgrade
|
| Total Assets | - | 15,181 | 10,780 | 9,849 | 8,566 | 7,747 | Upgrade
|
| Accounts Payable | - | 4,563 | 1,965 | 2,279 | 1,904 | 1,784 | Upgrade
|
| Accrued Expenses | - | 602.7 | 767.2 | 852.3 | 785.3 | 736.6 | Upgrade
|
| Current Portion of Leases | - | 62.8 | 18.1 | 35.2 | 36.1 | 35.1 | Upgrade
|
| Current Income Taxes Payable | - | 106.4 | 66.6 | 24.2 | 49.4 | 56.3 | Upgrade
|
| Current Unearned Revenue | - | 722.4 | 490.5 | 398 | 306.9 | 128.3 | Upgrade
|
| Other Current Liabilities | - | 972.7 | 263.7 | 250.8 | 244.4 | 295 | Upgrade
|
| Total Current Liabilities | - | 7,030 | 3,571 | 3,839 | 3,327 | 3,035 | Upgrade
|
| Long-Term Leases | - | 294.5 | 27.8 | 36.9 | 50.2 | 86.3 | Upgrade
|
| Other Long-Term Liabilities | - | 99.5 | 17.7 | 16.6 | 26.8 | 23.3 | Upgrade
|
| Total Liabilities | - | 7,478 | 3,661 | 3,962 | 3,452 | 3,185 | Upgrade
|
| Common Stock | - | 50 | 50 | 50 | 50 | 50 | Upgrade
|
| Retained Earnings | - | 6,859 | 6,313 | 5,088 | 4,321 | 3,772 | Upgrade
|
| Comprehensive Income & Other | - | 795 | 756.4 | 749.2 | 743 | 739.4 | Upgrade
|
| Shareholders' Equity | 7,704 | 7,704 | 7,119 | 5,887 | 5,114 | 4,562 | Upgrade
|
| Total Liabilities & Equity | - | 15,181 | 10,780 | 9,849 | 8,566 | 7,747 | Upgrade
|
| Total Debt | 357.3 | 357.3 | 45.9 | 72.1 | 86.3 | 121.4 | Upgrade
|
| Net Cash (Debt) | 5,004 | 5,004 | 5,010 | 4,931 | 4,398 | 3,402 | Upgrade
|
| Net Cash Growth | -0.11% | -0.11% | 1.59% | 12.13% | 29.27% | 41.36% | Upgrade
|
| Net Cash Per Share | 200.12 | 200.16 | 200.39 | 197.25 | 175.92 | 136.08 | Upgrade
|
| Filing Date Shares Outstanding | 25 | 25 | 25 | 25 | 25 | 25 | Upgrade
|
| Total Common Shares Outstanding | 25 | 25 | 25 | 25 | 25 | 25 | Upgrade
|
| Working Capital | - | 6,394 | 5,756 | 4,515 | 3,730 | 3,153 | Upgrade
|
| Book Value Per Share | 308.14 | 308.14 | 284.77 | 235.48 | 204.56 | 182.47 | Upgrade
|
| Tangible Book Value | 7,697 | 7,697 | 7,098 | 5,887 | 5,114 | 4,562 | Upgrade
|
| Tangible Book Value Per Share | 307.88 | 307.88 | 283.92 | 235.48 | 204.56 | 182.47 | Upgrade
|
| Land | - | 4.9 | 4.9 | 4.9 | 4.9 | 4.9 | Upgrade
|
| Buildings | - | 427 | 427 | 421.3 | 415.2 | 383.4 | Upgrade
|
| Machinery | - | 1,155 | 1,208 | 1,154 | 1,082 | 1,023 | Upgrade
|
| Construction In Progress | - | - | 2.7 | 13.3 | 22 | 40.2 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.